Biotransformation of isoflavone using enzymatic reactions

Article abstract of DOI:10.3390/molecules18033028

The roles of cytochrome P450 monooxygenases (CYPs) from Streptomyces spp. which are called the treasure islands for natural products for medicine and antibiotics are not well understood. Substrate specificity studies on CYPs may give a solution for elucidation of their roles. Based on homology sequence information, the CYP105D7 of a soluble cytochrome P450 known as heme protein from Streptomyces avermitilis MA4680 was expressed using the T7 promoter of the bacterial expression vector pET24ma, over-expressed in Escherichia coli system and characterized. An engineered whole cell system for daidzein hydroxylation was constructed using an exogenous electron transport system from ferredoxin reductase (PdR) and ferredoxin (Pdx). Also, an in vitro reaction study showed the purified CYP105D7 enzyme, using NADH-dependent-reducing equivalents of a redox partner from Pseudomonas putida, hydroxylated daidzein at the 3' position of the B ring to produce 7,3,'4' trihydroxyisoflavone. The hydroxylated position was confirmed by GC-MS analysis. The turnover number of the enzyme was 0.69 μmol 7,3,'4'-trihydroxyisoflavone produced per μmol P450 per min. This enzyme CYP105D7 represents a novel type of 3'-hydroxylase for daidzein hydroxylation. A P450 inhibitor such as coumarin significantly (ca.98%) inhibited the daidzein hydroxylation activity.

Full text of DOI:10.3390/molecules18033028

Molecules 2013, 18, 3028-3040; doi:10.3390/molecules18033028
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Biotransformation of Isoflavone Using Enzymatic Reactions
Changhyun Roh
Division of Biotechnology, Advanced Radiation Technology Institute (ARTI),
Korea Atomic Energy Research Institute (KAERI), 1266, Sinjeong-dong, Jeongeup,
Jeonbuk 580-185, Korea; E-Mail: chroh@kaeri.re.kr; Tel.: +82-63-570-3133; Fax: +82-63-570-3139
Received: 28 January 2013; in revised form: 25 February 2013 / Accepted: 4 March 2013 /
Published: 6 March 2013
Abstract: The roles of cytochrome P450 monooxygenases (CYPs) from Streptomyces spp.
which are called the “treasure islands” for natural products for medicine and antibiotics are
not well understood. Substrate specificity studies on CYPs may give a solution for
elucidation of their roles. Based on homology sequence information, the CYP105D7 of a
soluble cytochrome P450 known as heme protein from Streptomyces avermitilis MA4680
was expressed using the T7 promoter of the bacterial expression vector pET24ma,
over-expressed in Escherichia coli system and characterized. An engineered whole cell
system for daidzein hydroxylation was constructed using an exogenous electron transport
system from ferredoxin reductase (PdR) and ferredoxin (Pdx). Also, an in vitro reaction
study showed the purified CYP105D7 enzyme, using NADH-dependent-reducing
equivalents of a redox partner from Pseudomonas putida, hydroxylated daidzein at the 3'
position of the B ring to produce 7,3,'4' trihydroxyisoflavone. The hydroxylated position
was confirmed by GC-MS analysis. The turnover number of the enzyme was 0.69 μmol
7,3,'4'-trihydroxyisoflavone produced per μmol P450 per min. This enzyme CYP105D7
represents a novel type of 3'-hydroxylase for daidzein hydroxylation. A P450 inhibitor such
as coumarin significantly (ca.98%) inhibited the daidzein hydroxylation activity.
Keywords: enzyme; isoflavone; bioactive compound; hydroxylation; biocatalyst
1. Introduction
Recently, ortho-dihydroxyisoflavones (7,8,4'-trihydroxyisoflavone, 6,7,4'-trihdyroxyisoflavone and
7,3',4'-trihydroxyisoflavone) are of growing scientific interest to enhance their health-related
applications in humans. The isoflavone compounds hydroxylated at a specific ortho position have

Molecules 2013, 18
3029
potent antioxidant properties that contribute to their cholesterol-lowering effect, cardiovascular
protective, anti-tumor and anti-carcinogenic properties [1–7]. Furthermore, these compounds are
known to display anti-inflammatory and anti-allergenic activity, and acts as potent tyrosinase inhibitors
which is associated with inhibition of melanin formation [6,8]. According to many biological effect
studies, 7,3',4'-trihydroxyisoflavones have received much attention in recent years due to their
potentially beneficial estrogenic, antioxidant, and anticancer properties in humans [1,9]. Furthermore,
7,3',4'-trihydroxyisoflavone exhibited more effective antioxidant activity using the oxygen radical
absorbance capacity (ORAC) assay as well as the oxidation of low-density lipoproteins (LDL) assay [6,10].
In general, monooxygenases act as oxidants in a range of reactions, including the transfer of
molecular oxygen to X-H bonds of a substrate. Among the monooxygenase enzymes, P450s are
proficient at highly regio-specific hydroxylation reactions. Cytochromes P450 (CYPs) are heme-
containing enzymes that play a major role in the metabolism of xenobiotics, including drugs,
carcinogens, and environmental chemicals, as well as endogenous compounds such as steroids and
fatty acids. This enzyme is very common in eukaryotic and prokaryotic systems and responsible for
various metabolizing activities as a monooxygenase. The usefulness of the P450 monooxygenases
consists in the importance of their bioconversion activities of water insoluble chemicals into soluble
ones by the introduction of single oxygens via hydroxylation reaction [11–14]. Most P450s catalyze
two-electron oxidation reactions of organic substrates coupled to O-transfer [Equation (1)] Dioxygen
and the substrate (RH) bind at the heme active site and electrons from NADPH act to cleave the
O–O bond leaving a high valent oxo-heme moiety that is capable of O-insertion into an otherwise
inert C–H bond:
NAD(P)H + RH + O2 + H+ → NAD(P)+ + ROH + H2O
(1)
Nowadays, many of the P450 monooxygenases have been reported in prokaryotes like the
Actinomycetes, which have been intensively studied for their importance as industrial microorganisms
in producing various kinds of antibiotics and other bioactive substances. By an appropriate
involvement of P450 enzymes, many bioactive compounds are produced in Actinomycetes. Taylor et al.
reported that CYP105D1 from Streptomyces griseus has catalytic capacity in the hydroxylation of the
steroid testosterone, warfarin and naphthoflavone compounds [15].
Recently, due to the completion of the genome sequences of many microorganisms, it appears to be
eminently possible to capture specific genes from the whole genome of a particular microorganism.
Especially, Actinomycetes strains produce many useful natural compounds and metabolites as well as
polyketide biosynthesis [16–18]. Among these strains, Streptomyces avermitilis MA4680 produces
many useful antibiotics such as avermectin, oligomycin, geosmin, filipin, and pentalenolactone. The
genome sequence of this strain was published by the Omura group in 2003 [19], revealing 33 putative
CYP genes. Consequently, based on sequence homology information from Streptomyces avermitilis
MA4680 genome, it was possible to elucidate the characterization of CYP105D7, which is involved in
daidzein hydroxylation. The goal of this study was to examine the capability of engineered metabolism
to transform daidzein for the purposes of converting it into 7,3',4'-trihydroxyisoflavone.

Molecules 2013, 18
3030
2. Results and Discussion
2.1. Chemical Structure of 7,3',4'-Trihydroxyisoflavone from Daidzein
The chemical structure of daidzein, known as a phytoestrogen, is very similar that of the human
hormone estrogen. The basic structural unit of the daidzein comprises two benzene rings (A and B),
which are linked via a heterocyclic pyrone ring (C). Thus, the structure of 7,3',4'-trihydroxyisoflavone
implies the hydroxylation of daidzein at position C3' of the B-ring. The strategy for daidzein
hydroxylation is represented in Scheme 1.
Scheme 1. Representative scheme of the hydroxylation in the 3'-position of the daidzein
catalyzed by CYP105D7 with a suitable redox partner.
2.2. Identification and Functional Construction of CYP105D7 and Redox Partner in E. coli System
Since CYP105D1 used naphthoflavone as a substrate, its sequence homology was searched on a
NCBI database. Eight high homology P450 genes were found in the database, such as P450 from
Streptomyces griseus (GenBank accession no. P26911), P450 from Streptomyces avermitilis MA4680
(GenBank accession no. BAC75180), P450 from Streptomyces lividans (GenBank accession no.
AAC25766), P450 from Streptomyces coelicolor A3(2) (GenBank accession no. NP_625076), P450
from Streptomyces tubercidicus (GenBank accession no. AAT34969), P450 from Streptomyces
griseolus (GenBank accession no. P18326), P450 from Streptomyces sp. TM-7 (GenBank accession
no. BAE78754) and P450 from Streptomyces carbophilus (GenBank accession no. Q59831). Among
them, one (GenBank accession no. BAC75180) was chosen because it was translated well in the E. coli
host system. The size of the gene orf (cyp28) was 1,215 bp, encoding a cytochrome P450 protein
(CYP105D7) with molecular mass of 44.5 kDa. The sequence analysis by Clustal X is shown in Figure 1.
Both the oxygen-binding motif and heme domain sequences as well as the EXXR motif in the K helix
are shown with a box. The three component electron transfer combination was constructed in the
Escherichia coli system for whole cell-mediated daidzein hydroxylation by coexpression of the
corresponding coding sequences from two plasmids (Figure 2A). The developed system in this study
was inserted in two plasmids containing different selection markers to enable the construct to be
coexpressed stably in an E. coli strain. The presence of both plasmids in the expression strain was
assured by growing the LB media containing the antibiotics kanamycin and ampicillin. In this
coexpression system, all three proteins involved in the E. coli system as a host were organized.

Molecules 2013, 18
Figure 1. Cytochrome P450 alignments of the amino acid sequence with other bacterial
3031
strains. P26911; CYP from Streptomyces griseus, BAC75180; CYP from Streptomyces
avermitilis MA4680, AAC25766; CYP from Streptomyces lividans, NP_625076; CYP
from Streptomyces coelicolor A3(2), AAT34969; CYP from Streptomyces tubercidicus,
P18326; CYP from Streptomyces griseolus, BAE78754; CYP from Streptomyces sp. TM-7,
Q59831; CYP from Streptomyces carbophilus. Multiple sequence alignment of conserved
motifs in P450 enzymes identified. Both oxygen-binding motif and heme domain
sequences as well as the EXXR motif in the K helix are shown. Amino acids conserved in
the P450s listed are shown. The Cys residue that coordinates the heme is indicated by an
arrow. Alignments were performed with the CLUSTAL X 1.83. (*) Identical residues in
the different enzymes; (:) conserved substitutions; (.) semi-conserved substitutions.
2.3. Overexpression and Purification of CYP105D7, PdR and Pdx
Heterologous coexpression of CYP105D7, PdR and Pdx in the E. coli system was performed. Three
proteins with molecular weight of about 45 kDa (P450), 46 kDa (ferredoxin reductase) and 12 kDa
(ferredoxin) were visible on Coomassie staining of SDS-PAGE (Figure 2B). The CYP105D7 protein
was purified by a single chromatography step on a Ni2+ chelate affinity chromatography. N-terminal
His-tag P450bioI showed a molecular mass of approximately 45 kDa in a SDS-PAGE (Figure 2C).
The amount of purified protein was calculated to be approximately 200 μM·L−1 using the extinction
coefficient for oxidized CYP105D7 of ε418 = 181 mM−1 cm−1. Also, purification of the N-terminal
His-tagged ferredoxin reductase and ferredoxin was performed using the same procedures as described
above (Figure 2D,E).

Molecules 2013, 18
Figure 2. (A) A schematic CYP105D7 and PdR/Pdx coexpression plasmids in E. coli
3032
system. CYP105D7 is encoded on the 6.5 kb constructed pET24ma+_cyp28 under control
of a T7 promoter with IPTG induction system. The 7.0 kb plasmid pDuet-PdR-Pdx
contains two copies of the T7 promoter and a transcription terminator; (B) SDS-PAGE
13% gel showing the coexpressed proteins of CYP105D7 and PdR/Pdx. lane M, protein
marker; lane 1, before induction form of CYP105D7 and PdR/Pdx; lane 2, total form of
CYP105D7 and PdR/Pdx; lane 3, soluble form of CYP105D7 and PdR/Pdx; (C) SDS-PAGE
12% gel showing CYP105D7 with His-tag. M, protein marker; lane 1, before induction
form of CYP105D7; lane 2, total form of CYP105D7; lane 3, soluble form of CYP105D7;
lane 4, His-Tag form of CYP105D7; (D) SDS-PAGE 12% gel showing PdR with His-tag.
M, protein marker; lane 1, before induction form of PdR; lane 2, total form of PdR; lane 3,
soluble form of PdR; lane 4, His-Tag form of PdR; (E) SDS-PAGE 13% gel showing Pdx
with His-tag. M, protein marker; lane 1, before induction form of Pdx; lane 2, total form of
Pdx; lane 3, soluble form of Pdx; lane 4, His-Tag form of Pdx. Arrow represents protein,
respectively.
2.4. Characterization of Recombinant CYP105D7 and Kinetic Parameter
Their activities of the coexpressed proteins were examined by UV-Vis spectroscopy, which
revealed the typical characteristics of P450, a heme Soret peak at 420 nm (low spin) in the absence of
carbon monoxide. The spectrum of the dithionite-reduced and CO-bound form showed the well known
absorption maximum at 450 nm (Figure 3). In Table 1, we showed the apparent specificity constants
(kcat/Km) by fitting the concentration-dependent data to the linear region of the Michaelis-Menten
Lineweaver-Burke curve. The kcat/Km value for daidzein hydroxylation is approximately 0.69

Molecules 2013, 18
3033
(Km = 21.83 μM, kcat = 15.01 min−1). For kinetic parameters, CYP105D7 with a redox partner
showed a typical hyperbolic profile which means the dependency of reaction rate on substrate
concentration, corresponding to classic Michaelis-Menten equation. In this system, NADH was used as
general electron donor in the in vitro reaction.
Figure 3. UV-visible absorbance spectra of expressed CYP105D7. Dashed line: oxidized
CYP105D7, Dotted line: Reduced form with dithionite, Solid line: CO-bound form spectra
with dithionite. The insert represents the CO difference spectra.
Table 1. Catalytic kinetic analysis for NADH-dependent hydroxylation of daidzein from CYP105D7.
Substrate
Km [μM]
kcat [min−1]
kcat/Km [μM−1/min−1] *
Daidzein
21.83 ± 6.3
15.01 ± 0.6
0.69
* Reaction was performed in potassium phosphate buffer at pH 7.5 in the presence of 10 mM NADH;
The same protein concentration of PdR and Pdx was added for reaction.
2.5. Hydroxylation of Daidzein by CYP105D7 in Vivo and in Vitro System
For recombinant whole cell reactions, the schematic strategy for daidzein hydroxylation was
orchestrated as shown in Figure 4A. For the in vitro system, the delivery of the two electrons from
NADH to the P450 must be organized as seen in Figure 4B as well. Daidzein was hydroxylated to
7,3',4'-trihydroxyisoflavone, indicating PdR and Pdx are functional as active artificial electron
transport partners for CYP105D7 activity. The identification of the hydroxylated products detected in
the whole cell and enzyme reaction was performed. The product, 7,3',4'-trihydroxyisoflavone, was
clearly detected by HPLC analysis in the in vivo and in vitro reactions (data not shown). In the in vitro
system, there was no activity when the NADH cofactor was omitted (data not shown). To further
verify the hydroxylation position of the product formed from daidzein, GC/MS analysis was performed
after trimethylsilylation with BSTFA. The reaction product showed identical retention time (RT = 24.1 min)
to that of authentic 7,3',4'-trihydroxyisoflavone (Figure 5A). In the mass spectrum of the product an
m/z 486 peak for 7,3',4'-trihydroxyisoflavone was observed, indicating the hydroxylation at C3' of
B-ring position (Figure 5B). The endogenous redox partner from E. coli did not function and give no

Molecules 2013, 18
3034
activity in daidzein hydroxylation in the whole cell reaction with CYP105D7. Figure 5 shows GC-MS
mass spectra of daidzein and the 3'-hydroxylated daidzein product obtained with PdR and Pdx.
Figure 4. Schematic representation of the in vivo and in vitro reaction designed for
daidzein hydroxylation.
Figure 5. Gas Chromatography-Mass Spectroscopy analyses for daidzein hydroxylation in vivo
and in vitro reaction. (A) GC chromatograms of the hydroxylated metabolite of daidzein.
a, authentic daidzein; b, authentic 7,3',4'-trihydroxyisoflavone c, in vivo reaction with
heterologously expressed P450 and redox partner; d, in vivo reaction with P450;
e, in vitro reaction with P450 and PdR/Pdx; f, in vitro reaction with P450;
(B) Representative electron impact mass spectra of TMS derivatives of daidzein and
metabolite. g, mass spectrum of authentic daidzein (Peak, 1); h, mass spectrum of
authentic 7,3',4'-trihydroxyisoflavone, (Peak, 2); i, mass spectrum of reactant, 7,3',4'-
trihydroxyisoflavone (Peak, 4); j, mass spectrum of reactant, 7,3',4'-trihydroxyisoflavone
(Peak, 7). Peak 3, 5, 6 and 8 represent mass spectra of daidzein. Retention times: daidzein,
19.5 min and 7,3',4'-trihydroxyisoflavone, 24.1 min.

Molecules 2013, 18
3035
2.6. Effect of P450 Inhibitors on the Hydroxylation of Daidzein
The effect of common P450 inhibitors such as coumarin, erythromycin and ketoconazole [20–22]
on the hydroxylation of daidzein was examined by adding 0.5 mM of these inhibitors. The results are
shown in Table 2. Among all the P450 inhibitors examined the hydroxylation activity was significantly
inhibited by coumarin. Ketoconazole inhibited the reaction by 86%. Erythromycin inhibited the
daidzein hydroxylation reaction by 37%.
Table 2. Effect of P450 inhibitors on hydroxylation of daidzein.
P450 inhibitor *
None
Reactive activity (%)
100
2
Coumarin
Erythromycin
Ketoconazole
63
14
* Each inhibitor reaction was performed at the final concentration of 50 μM; The reaction of daidzein was
performed at 30 °C.
3. Experimental
3.1. Chemicals
Daidzein, 7,3',4'-trihydroxyisoflavone, quinidine, coumarin and erythromycin were obtained from
Sigma-Aldrich Chemical Co (Yongin, Korea). Ketoconazole and N,O-bis(trimethylsily)trifluoroacetamide
were purchased from Fluka (Yongin, Korea). All other chemicals were of the highest grade available.
3.2. Plasmid Construction
For the co-expression system; the pET24ma vector was used for construction of the P450-plasmid
pET24ma_cyp28. The other expression vector (Cat. no. 71146-3; Novagen, Madison, WI, USA) was
constructed for the redox partners ferredoxin reductase (PdR) and ferredoxin (Pdx)-plasmid
pDuet-PdR-Pdx. For his-tag purification; pET28a+ vector (Cat. no. 69864-3; Novagen) was used. The
plasmid construction was carried out with E. coli (DH5α, Novagen). The expression of target genes
were performed using E. coli BL21 (DE3, Novagen).
3.3. Cloning of CYP105D7 from Streptomyces avermitilis MA4680
The strain, Streptomyces avermitilis MA4680, was obtained from the Microbial Resources Center
(SNU, Seoul, South Korea). The genomic DNA of strain was prepared by G-spin genomic DNA
extraction kit (Intron, Seoul, Korea) and used as template for PCR. The P450 gene was amplified by
PCR using a set of specific primers; sense, 5'-CTGCATATGACAGAGCCCGGTACGT-3'; antisense,
5'-CATGGATCCTTACCAGGTCACGGGGAGTTC-3', where italic letters indicate restriction enzyme
site NdeI and BamHI, respectively. The PCR reaction conditions as follows: 35 cycles of denaturation
for 1 min at 94 °C, annealing for 1 min at 68 °C, and extension for 1 min 30 s at 72 °C. The PCR
product was cloned into NdeI/BamHI sites of expression vector pET24ma. For His-tag plasmid of

Molecules 2013, 18
3036
P450, it was N-terminally attached (Novagen). Also, it was attached N-terminally at expression vector
pET28a+ for cyp28.
3.4. Coexpression of CYP105D7 and Redox Partner for in Vivo System
The plasmids of P450 and redox partner were transformed together into E.coli BL21(DE3). The
transformant was grown in Luria-Bertani (LB) medium containing 100 μg·mL−1 of kanamycin and
ampicillin at 37 °C until the cell concentration reached to an OD600nm of 0.6, and isopropyl-thio-β-D-
galactopyranoside (IPTG) and δ-aminolevlunic acid as heme precursor were added to a final
concentration of 0.5 mM, followed by growing for overnight at 28 °C. Cells were harvested by
centrifugation and used for direct reaction.
3.5. Purification of CYP105D7 and Redox Partner for in Vitro System
For His-tag purification of P450, ferredoxin reductase and ferredoxin, each cells were washed three
times using Phosphate Buffered Saline (PBS) containing 137 mM NaCl, 2.7 mM, 10 mM Na2HPO4
and 2 mM KH2PO4. Then, cells were harvested by centrifugation at 4,000 rpm for 30 min at 4 °C and
resuspended in sonication buffer (pH 7.5) containing 100 mM Na2HPO4, 2 mM EDTA and 0.5 mM
PMSF, 1 mM DTT, 1 mM MgCl2. Cells were disrupted by Sonicator (Misoni S3000, Canton, MA,
USA). The cell debris was removed by centrifugation at 15,000 rpm for 30 min. The clear supernatant
was collected and the soluble proteins (P450, PdR and Pdx) were purified with his-tag affinity column
(QIAGEN GmbH, Hilden, Germany). Their proteins with (His)6-tag were N-terminally attached using
a Ni-NTA resin (QIAGEN GmbH). The column-bound enzyme was washed with 50 mM potassium
phosphate buffer (pH 7.5) containing 500 mM sodium chloride and 50 mM imidazole. Elution was
performed by increasing the imidazole concentration to 250 mM. Imidazole and sodium chloride were
removed by dialysis against 50 mM phosphate buffer (pH 7.5) overnight. The purity of the enzyme
was estimated by SDS-PAGE in the eluted fractions. The protein concentration was determined as
described by Bradford [23] with bovine serum albumin as the standard. Enzyme samples were
supplemented with 50% glycerol and stored at −20 °C until use.
3.6. CYP105D7 Concentration Measurement and Absorption Spectra
The carbon monoxide (CO) difference spectra were measured on an UV/vis spectrometer
(Spectronic, Genesys, Milton Roy, Rochester, NY, USA). The concentration of CYP105D7 was
measured based on CO difference spectra, using an extinction coefficient of 91 mM−1 cm−1 at
450 nm [24]. The concentrations of redox partners were determined using extinction coefficients of
11.1 mM−1 cm−1 at 415 nm for ferredoxin and 10.0 mM−1 cm−1 at 454 nm for ferredoxin reductase [25].
3.7. Kinetic Study for Substrate Activity with CYP105D7
For kinetic study, NADH oxidation was measured by the absorption decrease at 340 nm with an
UV/vis spectrometry (Thermo Labsystems, Beverly, MA, USA). A solution containing 100 µL of
potassium phosphate buffer (pH 7.5), 20 μL of each substrate concentration solution in DMSO and 20 µL
of enzyme solutions (CYP105D7, PdR and Pdx, 10 µmol/mL, respectively) was incubated for 5 min in

Molecules 2013, 18
3037
96 well microplate. The reaction was started by adding 20 μL of 10 mM NADH solution. For
determination of kinetic parameters, a substrate concentration range of 31.25–500 μM was used. All
data were fitted to the Lineweaver-Burke equation by linear regression. As a reference sample, NADH
consumption rates at 340 nm were measured without substrate.
3.8. Daidzein Hydroxylation in Vivo and in Vitro System
For whole cell reaction of E.coli with coexpressed CYP105D7 and redox partner (ferredoxin
reductase, ferredoxin), 50 mL of E.coli cell culture containing the overexpressed three enzymes was
harvested and resuspended in 10 mL of LB broth containing 100 μg·mL−1 of kanamycin and
ampicillin. Daidzein as substrate, at the final concentration of 50 μM was added into the resuspension
cell, and was incubated on a shaking conical flask for about 6 h at 30 °C. For control, the
overexpressed CYP105D7 without redox partner was performed at same conditions. The three
volumes of ethyl acetate (Junsei, Cuisine, Japan) were then added into the reactants and vortexed
thoroughly. The mixture was separated into aqueous and ethyl acetate phases by centrifugation, and
the ethyl acetate phase was evaporated in centrifugal vacuum concentrator (BioTron, Bucheon, Korea).
The dried reactant was dissolved in methanol (Merck, Darmstadt, Germany). For in vitro reaction
using purified CYP105D7, ferredoxin reductase (PdR) and ferredoxin (Pdx), one hundred μg of the
purified proteins were reacted with 0.5 mM NADH and 50 μM daidzein of final concentration in
100 mM potassium phosphate buffer (pH 7.2) at 20 °C for 2 h. For control, NADH was excluded from
the reaction.
3.9. High Performance Liquid Chromatography (HPLC) Analysis of Product
The reactant was analyzed using a HPLC (Autochro-3000, Young Lin, Anyang, Korea) equipped
with a UV/Vis detector and a Waters symmetry C18 column (4.6 × 150 mm, 5.0 μM particle size,
Waters, Milford, MA, USA). The flow rate was 1 mL·min−1 and the injection volume was 10 μL. The
solvent used was acetonitrile (CH3CN):water:trifluoroacetic Acid (TFA) = 3:7:0.1% (v/v/v).
3.10. Gas Chromatography (GC)/Mass Spectrometry (MS) Analysis
For GC/MS analysis, reaction metabolites were converted to their TMS (trimethylsilyl) derivatives
by heating for 20 min at 60 °C with BSTFA (N,O-bis(trimethylsily)trifluoroacetamide). GC/MS was
carried out on a Finnigan MAT system (Gas chromatograph model GCQ, HP 19091J-433, Thermo
Finnigan, Austin, TX, USA) connected to an ion trap mass detector. The TMS-derivatives were
analyzed using a nonpolar capillary column (5% phenyl methyl siloxane capillary 30 m × 250 μm i.d.,
0.25 μm film thickness, HP-5) and a linear temperature gradient (60 °C 1 min, 30 °C/min to 250 °C,
hold for 10 min, 1 °C/min to 275 °C, and hold for 3 min). The injector port temperature was 100 °C.
Scan spectrum was 100~600 m/z and mass spectra were obtained by electron impact ionization at 70 eV.
The selected ion mode (SIM) was used for the detection of daidzein and its hydroxylated metabolite.

Molecules 2013, 18
3038
3.11. Effects of P450 Inhibitors on Hydroxylation of Daidzein
The used P450 inhibitors were coumarin, erythromycin and ketoconazole. The inhibition of
daidzein hydroxylation by typical cytochrome P450 inhibitors was studied in the presence of 0.5 mM
cytochrome P450 inhibitors with coexpressed recombinant enzymes. Inhibitors and daidzein were
added at the same time for reaction, the conversion of product was determined by HPLC. As control,
the same reaction condition without the addition of inhibitors was used. The extent of inhibition was
analyzed by comparing quantative analysis of HPLC peak of product from control with those from
reaction containing inhibitors.
4. Conclusions
In this study, our goal was to examine the capability of an engineered organism to transform
daidzein for the purpose of converting it into 7,3',4'-trihydroxyisoflavone. We describe the
construction of a whole cell bioconversion system for daidzein hydroxylation using a co-expressed
redox partner system of ferredoxin reductase (PdR) and ferredoxin (Pdx) with CYP105D7. Here, we
were able to identify a novel daidzein 3'-hydroxylase based on homology sequence information from
substrate specificity studies. To the best of our knowledge, CYP105D7 is first microbial P450 for
daidzein hydroxylation at the C-3' position of the B-ring. For hydroxylation, the system was composed
of three components: NADH-dependent and FAD-containing ferredoxin reductase (FdR), ferredoxin
(Fdx) as an electron-transfer protein and cytochrome P450, which acts as a monooxygenase in the
microbial system. Here, we describe the design of a whole cell bioconversion system for daidzein
using two plasmids composed of the electron transfer system PdR and Pdx and microbial CYP105D7.
In a two plasmid approach, the genes of PdR and Pdx are constructed on the first plasmid, whereas the
second plasmid contains the coding sequence for the expression of microbial CYP105D7. The
ferredoxin protein delivers, consecutively, two electrons to the heme active site of the P450 in a
carefully orchestrated process which ultimately leads to the observed hydroxylation activity. Redox
equivalents are transferred from NADH via the proteins PdR and Pdx to enzyme CYP105D7
converting the daidzein hydroxylation. The CYP105D7 added hydroxyl group to B ring of daidzein to
form 7,3,'4,-trihydroxyisoflavone in E. coli system with a redox partner.
Through an in vitro reaction, we studied an isoflavone hydroxylase activity of CYP105D7 using an
artificial electron transport system, consisting of ferredoxin reductase and ferredoxin. The chemical
structure of the product was elucidated using GC-MS to confirm the location of the new hydroxyl
group. We demonstrated the enzyme-tailored hydroxylation of daidzein, as a proposed method for
structural modification of this substrate for further functional applications as a phytoestrogen compound.
Acknowledgments
This work was supported by a grant from the Creative Research Project of National R&D Projects,
Korea Atomic Energy Research Institute (KAERI), Korea.

Molecules 2013, 18
3039
References
1. Klus, K.; Barz, W. Formation of polyhydroxylated isoflavones from the soybean seed isoflavones
daidzein and glycitein by bacteria isolated from tempe. Arch. Microbiol. 1995, 164, 428–434.
2. Esaki, H.; Watanabe, R.; Osaka, T. Formation mechanism for potent antioxidative
o-dihydroxyisoflavones in soybeans fermented with Aspergillus saitori. Biosci. Biotechnol. Biochem.
2006, 63, 851–858.
3. Kulling, S.E.; Honig, D.M.; Simat, T.J.; Metzler, M. Oxidative in vitro metabolism of the soy
phytoestrogens daidzein and genistein. J. Agric. Food. Chem. 2000, 48, 4963–4972.
4. Kulling, S.E.; Honig, D.M.; Metzler, M. Oxidative metabolism of the soy isoflavones daidzein
and genistein in humans in vitro and in vivo. J. Agric. Food. Chem. 2001, 49, 3024–3033.
5. Hirota, A.; Inaba, M.; Chen, Y.C.; Abe, N.; Taki, S.; Yano, M.; Kawaii, S. Isolation of
8-hydroxyglycitein and 6-hydroxydaidzein from soybean miso. Biosci. Biotechnol. Biochem.
2004, 68, 1372–1374.
6. Rufer, C.E.; Kulling, S.E. Antioxidant activity of isoflavones and their major metabolites using
different in vitro assays. J. Agric. Food. Chem. 2006, 54, 2926–2931.
7. Rufer, C.E.; Maul, R.; Donauer, E.; Fabian, E.J.; Kulling, S.E. In vitro and in vivo metabolism of
the soy isoflavone glycitein. Mol. Nutr. Food Res. 2007, 51, 813–823.
8. Chang, T.S.; Ding, H.Y.; Lin, H.C. Identifying 6,7,4'-trihydroxyisoflavone as a Potent Tyrosinase
Inhibitor. Biosci. Biotech. Biochem. 2005, 69, 1999–2001.
9. Akiyama, T.; Ishida, J.; Nakagawa,S.; Ogawara, H.; Watanabe, S.; Itoh, N.; Shibuya, M.; Fukami, Y.
Genistein, a specific inhibitor of tyrosine specific protein kinases. J. Biol. Chem. 1987, 262,
5592–5595.
10. Rufer, C.E.; Glatt, H.; Kulling, S.E. Structural elucidation of hydroxylated metabolites of the
isoflavane equol by gas chromatography-mass spectrometry and high-performance liquid
chromatography-mass spectrometry. Drug. Metab. Dispos. 2006, 34, 51–60.
11. Ortiz de Montellano, P.R. Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed.;
Kluwer Academic/Plenum Publishers: New York, NY, USA.
12. Bernhardt, R. Cytochromes P450 as versatile biocatalysts. J. Biotechnol. 2006, 124, 128–145.
13. Urlacher, V.; Schmid, R.D. Biotransformations using prokaryotic P450 monooxygenases. Curr.
Opin. Biotechnol. 2002, 13, 557–564.
14. Holland, H.L.; Weber, H.K. Enzymatic hydroxylation reactions. Curr. Opin. Biotechnol. 2000,
11, 547–553.
15. Taylor, M.; Lamb, D.C.; Cannell, R.; Dawson, M.; Kelly, S.L. Cytochrome P450105D1
(CYP105D1) from Streptomyces griseus: Heterologous expression, activity, and activation effects
of multiple xenobiotics. Biochem. Biophys. Res. Commun. 1999, 263, 838–842.
16. Staunton, J.; Weissman, K.J. Polyketide biosynthesis: A millennium review. Nat. Prod. Rep.
2001, 18, 380–416.
17. Shen, B. Polyketide biosynthesis beyond the type I, II and III polyketide synthase paradigms.
Curr. Opin. Chem. Biol. 2003, 7, 285–295.
18. Lee, K.W.; Joo, H.S.; Yang, Y.H.; Song, E.J.; Kim, B.G. Proteomics for Streptomyces:
“Industrial Proteomics” for Antibiotics. J. Microbiol. Biotechnol. 2006, 16, 331–348.

Molecules 2013, 18
3040
19. Ikeda, H.; Ishikawa, J.; Hanamoto, A.; Shinose, M.; Kikuchi, H.; Shiba, T.; Sakaki, Y.; Hattori, M.;
Omura, S. Complete genome sequence and comparative analysis of the industrial microorganism
Streptomyces avermitilis. Nat. Biotechnol. 2003, 21, 526–531.
20. Liu, W.; Rosazza, J.P. A soluble Bacillus cereus cytochrome P-450cin system catalyzes
1,4-cineole hydroxylations. Appl. Environ. Microbiol. 1993, 59, 3889–3893.
21. Orita, M.; Yamamoto, S.; Katayama, N.; Aoki, M.; Takayama, K.; Yamagiwa, Y.; Seki, N.;
Suzuki, H.; Kurihara, H.; Sakashita, H.; et al. Coumarin and Chromen-4-one analogues as
tautomerase inhibitors of macrophage migration inhibitory factor: Discovery and X-ray
Crystallography. J. Med. Chem. 2001, 44, 540–547.
22. Harris, R.; Wood, D.M.; Bottomley, L.; Blagg, S.; Owen, K.; Hughes, P.; Waring, R.H.
Phytoestrogens are potent inhibitors of estrogen sulfation: Implications for breast cancer risk and
treatment. J. Clin. Endocrinol. Metab. 2004, 89, 1779–1787.
23. Bradford, M. A rapid and sensitive method for the quantification of microgram quantities of
protein utilizing the principle of protein dye binding. Anal. Biochem. 1976, 72, 248–254.
24. Omura, T.; Sato, R.J.; The carbon monoxide-binding pigment of liver microsomes. I. Evidence
for its hemoprotein nature. J. Biol. Chem. 1964, 239, 2370–2378.
25. Gunsalus, I.C.; Wagner, G.C. [17] Bacterial p450cam methylene monooxygenase components:
Cytochrome m, putidaredoxin, and putidaredoxin reductase. Methods Enzymol. 1978, 52, 166–188.
Sample Availability: Not available.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).